NCT00121836View on ClinicalTrials.gov

A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

June 30, 2005

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Breast Cancer
Interventions
DRUG

Capecitabine

1000 mg/m² PO BID on Days 1-15 of each 3-week cycle

DRUG

Bevacizumab

15 mg IV on Day 1 of each 3-week cycle

Trial Locations (57)

14642

Rochester

20678

Prince Frederick

24211

Abingdon

28602

Hickory

29150

Sumter

29406

Charleston

29506

Florence

29902

Beaufort

29926

Hilton Head Island

30084

Tucker

30341

Atlanta

30901

Augusta

33435

Boynton Beach

33901

Fort Myers

33908

Fort Myers

33980

Port Charlotte

33990

Cape Coral

34102

Naples

34119

Naples

34135

Bonita Springs

34209

Bradenton

34232

Sarasota

34236

Sarasota

34292

Venice

35022

Birmingham

35205

Birmingham

35209

Birmingham

35211

Birmingham

35213

Birmingham

35235

Birmingham

44718

Canton

46202

Indianapolis

46219

Indianapolis

48909

Lansing

50702

Waterloo

53215

Milwaukee

60611

Chicago

64064

Kansas City

64111

Kansas City

64131

Kansas City

64154

Kansas City

66112

Kansas City

66210

Kansas City

68114

Omaha

68510

Lincoln

73112

Oklahoma City

89106

Las Vegas

90057

Los Angeles

91204

Glendale

91206

Glendale

91505

Burbank

92121

San Diego

06030

Farmington

04074

Scarborough

08724

Brick

07754

Neptune City

07701

Red Bank

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00121836 - A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter